UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdiction ...

SOMERVILLE, Mass., May 2, 2024 /PRNewswire/ -- Matterworks, Inc., whose foundational AI platform and predictive biology applications accelerate life sciences discovery and development, today announces additions to its leadership team. Matterworks is pleased to announce the appointments of Jennifer M. Campbell, Ph.D. to the position of Chief Scientific Officer and Niall O'Connor to the position of Chief Technology Officer. Dr. Campbell is a distinguished leader in mass spectrometry and molecular analysis, br ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis an ...

HCA Healthcare (HCA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this hospital operator have returned -5.7%, compared to the Zacks S&P 500 composite's -2.5% change. During this period, the Zacks Medical - Hospital industry, which HCA falls in, has lost 7.2%. The key question now is: What could be the stock's future direction? While media releases or ...

HCA Healthcare, Inc. (HCA) reported first-quarter 2024 adjusted earnings per share (EPS) of $5.36, which beat the Zacks Consensus Estimate by 7%. The bottom line improved 8.7% year over year. Revenues amounted to $17.3 billion, which improved 11.2% year over year in the quarter under review. The top line outpaced the consensus mark by 2.9%. The strong quarterly results benefited from expanding patient volumes and a higher number of surgeries, which contributed substantially to the top line of HCA Healthcare ...

财务数据和关键指标变化 - 第一季度每股调整后收益增长近9%至$5.36 [12] - 同店收入增长近9%,主要由于量增长和每等效入院收费增长3.5% [14] - 调整后EBITDA增长5.7%至$33.5亿 [23] - 经营活动产生的现金流为$24.5亿,资本支出$11亿,股票回购$11.2亿 [25] 各条业务线数据和关键指标变化 - 住院量增长6%,门诊手术量下降2%,主要受到日历因素影响 [12][13] - 急诊就诊量增长7%,心脏手术和康复入院也有良好增长 [12][13] - 商业保险量占等效入院的36%,去年为34% [13] - 病案混合指数略有上升,延续近年来的上升趋势 [13] 各个市场数据和关键指标变化 - 所有国内分部的住院量和等效入院都有增长 [12] - 麦迪凯德重新认定导致该业务量大幅下降,但被商业保险和医疗补助计划的增长所抵消 [13][39][54] 公司战略和发展方向及行业竞争 - 公司继续投资扩大网络,新增近5%的医疗服务点,床位容量增加2% [16] - 未来将继续保持谨慎的运营方式,同时适当投资战略议程 [16] - 公司看好行业需求增长的大背景,有信心实现长期目标 [10][11] 管理层对经营环境和未来前景的评论 - 公司基本面保持良好势头,一季度表现强劲 [10] - 管理层对公司的运营表现和未来前景保持乐观 [10][11][19] - 公司将继续保持谨慎的成本管控,同时适当投资以把握行业机遇 [16] 问答环节重要的提问和回答 问题1 **A.J. Rice 提问** 各业务线的表现情况,以及对全年的预期 [31] **Sam Hazen 回答** 公司各业务线均有较强增长,尤其是住院量,有56家医院增长超10% [32][33][34][35][36] 预计全年表现将优于指引范围 [79][80][81] 问题2 **Ann Hynes 提问** 麦迪凯德重新认定对公司的影响,以及两夜规则的影响 [38] **Bill Rutherford 回答** 麦迪凯德重新认定影响约20%的患者,但大部分转为商业保险或医疗补助计划,整体影响有限 [39][40] 两夜规则带来适度利好,但仍在观察中 [40] 问题3 **Pito Chickering 提问** 运营成本压力情况,以及Valesco业务表现 [42] **Bill Rutherford 回答** 专业费用和补充支付计划税费是主要因素,整体保持相对稳定 [43][44] Valesco业务表现优于预期 [22][43]

For the quarter ended March 2024, HCA Healthcare (HCA) reported revenue of $17.34 billion, up 11.2% over the same period last year. EPS came in at $5.36, compared to $4.93 in the year-ago quarter. The reported revenue represents a surprise of +2.93% over the Zacks Consensus Estimate of $16.84 billion. With the consensus EPS estimate being $5.01, the EPS surprise was +6.99%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

财务表现 - HCA Healthcare (HCA)在最新季度的每股收益为5.36美元，超过了Zacks Consensus Estimate的5.01美元[1] - HCA在过去四个季度中，三次超过了市场预期的每股收益[2] - HCA在2024年3月结束的季度实现了173.4亿美元的营收，超过了Zacks Consensus Estimate的2.93%[3] 股价表现 - HCA股价自年初以来上涨了约16.1%，表现优于标普500指数的5.8%[4]

Exhibit 99.1 FOR IMMEDIATE RELEASE INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS FIRST QUARTER 2024 RESULTS Nashville, Tenn., April 26, 2024 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2024. Key first quarter metrics (all percentage changes compare 1Q 2024 to 1Q 2023 unless otherwise noted): ● Revenues totaled $17.339 billion ● Net income attributable to HCA Healthca ...

HCA Healthcare, Inc. 盈利预期 - HCA Healthcare, Inc. 即将发布财报，分析师们最近对其盈利预期进行了积极修订[1][2] - 目前HCA的最准确盈利预期为每股5.69美元，高于Zacks Consensus Estimate的5.01美元，显示分析师们最近上调了对HCA的盈利预期[3] - 根据Zacks Earnings ESP的数据，HCA的盈利预期表现良好，加上Zacks Rank 2 (Buy)的评级，投资者可能会考虑在财报发布前投资该股[5]